349 related articles for article (PubMed ID: 21742805)
1. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
2. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
3. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
5. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
6. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
7. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
[TBL] [Abstract][Full Text] [Related]
8. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
9. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
10. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
13. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
14. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
15. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
[TBL] [Abstract][Full Text] [Related]
19. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
20. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Iwagami Y; Eguchi H; Nagano H; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Tomokuni A; Tomimaru Y; Mori M; Doki Y
Br J Cancer; 2013 Jul; 109(2):502-11. PubMed ID: 23799850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
